Maximum quantity allowed is 999
请选择数量
CAS RN: 120202-66-6 | 產品號碼: C2556
(S)-(+)-Clopidogrel Sulfate
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | C2556 |
純度/分析方法 
|
>98.0%(HPLC)(N) |
| 分子式 / 分子量 | C__1__6H__1__6ClNO__2S·H__2SO__4 = 419.89 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Refrigerated (0-10°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器
|
1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 120202-66-6 |
| 相關CAS RN
|
113665-84-2 |
| Reaxys-RN | 9967887 |
| PubChem Substance ID | 125308051 |
| MDL編號 | MFCD00876395 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Optical Isomer | max. 0.5 % |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Specific rotation [a]20/D | +54.0 to +58.0 deg(C=1, MeOH) |
| NMR | confirm to structure |
性質
| 比旋光 [α]D | 56° (C=1,MeOH) |
| 溶解性（可溶於） | Methanol |
GHS
相關法規
運輸資料
| HS編碼* | 2934.99-000 |
Application
(S)-(+)-Clopidogrel Sulfate: An Antiplatelet Agent Acting as a P2Y12 ADP Receptor Antagonist
(S)-(+)-Clopidogrel sulfate is a thienopyridine class inhibitor of platelet activation and aggregation through the binding the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets. (S)-(+)-Clopidogrel is must be metabolized by CYP450-2C19 enzymes in liver to produce the thiol active metabolite antagonizes binding irreversibly to the P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.1-4) On the other hand, the (R)-enantiomer has no antithrombotic activity.5) (S)-(+)-Clopidogrel has been often used in combination with acetylsalicylic acid (aspirin) [A2262] to the treatment of ischemic vascular disease.4) For your reference, [T2770] is a synthetic intermediate of (S)-(+)-clopidogrel. (The product is for research purpose only.)
References
- 1) P2Y12, a New Platelet ADP Receptor, Target of Clopidogrel
- 2) Identification of the platelet ADP receptor targeted by antithrombotic drugs
- 3) Clopidogrel: a review of its use in the prevention of thrombosis
- 4) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
- 5) Developments in the synthesis of the antiplatelet and antithrombotic drug (S)-clopidogrel (a review)
考研文獻
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。